We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Immune Response in Peripheral Blood of Patients With Colon Cancer

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00900432
First Posted: May 12, 2009
Last Update Posted: December 3, 2015
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
University of Arizona
May 9, 2009
May 12, 2009
December 3, 2015
July 2004
December 2008   (Final data collection date for primary outcome measure)
Quantitation of T cells specific for tumor peptides (carcinoembryonic antigen and MUC1) [ Time Frame: 3 months ]
Quantitation of T cells specific for tumor peptides (carcinoembryonic antigen and MUC1)
Complete list of historical versions of study NCT00900432 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Immune Response in Peripheral Blood of Patients With Colon Cancer
Immune Studies of Peripheral Blood From Patients With Malignant Disease Gastrointestinal Tract

RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that may occur in the immune system that may help kill cancer cells.

PURPOSE: This laboratory study is looking at anticancer immune responses in the peripheral blood of patients with colon cancer.

OBJECTIVES:

  • Quantify T cells specific for tumor peptides (carcinoembryonic antigen and MUC1) from the peripheral blood of patients with colon cancer.

OUTLINE: This is an open-label study.

Patients undergo blood collection at time of follow-up, surgery, thoracentesis, paracentesis, or leukapheresis (≤ 5 times per year). Blood is analyzed for tumor peptides (carcinoembryonic antigen and MUC1), circulating cytokines, and lymphocyte response by ELISA, ELISPOT, or intracellular flow.

PROJECTED ACCRUAL: A total of 140 patients will be accrued for this study.

Observational
Observational Model: Case-Only
Time Perspective: Prospective
Not Provided
Not Provided
Probability Sample
colon cancer
Colorectal Cancer
  • Other: immunoenzyme technique
  • Other: laboratory biomarker analysis
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
67
December 2008
December 2008   (Final data collection date for primary outcome measure)

DISEASE CHARACTERISTICS:

  • Diagnosis of colon cancer

PATIENT CHARACTERISTICS:

  • Not specified

PRIOR CONCURRENT THERAPY:

  • Not specified
Sexes Eligible for Study: All
Child, Adult, Senior
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00900432
04-0331-01
P50CA095060 ( U.S. NIH Grant/Contract )
P30CA023074 ( U.S. NIH Grant/Contract )
UARIZ-04-81 ( Other Identifier: CDR0000491215 )
Yes
Not Provided
Not Provided
University of Arizona
University of Arizona
National Cancer Institute (NCI)
Study Chair: Michael Demeure, MD University of Arizona
University of Arizona
August 2012